Gateway? 克隆组

NR-19605?? Yersinia pestis, Strain KIM, Gateway? Clone Set, Recombinant in Escherichia coli, Plate 9(Clones)|Yersinia pestis|Yersinia pestis, Strain KIM, Gateway? Clone Set, Recombinant in Escherichia coli, Plate 9|-80°C or colder|Pathogen Functional Genomics Resource Center at the J. Craig Venter InstituteAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Yersinia pestis, Strain KIM, Gateway^? Clone Set, Recombinant in Escherichia coli, Plate 9, NR-19605."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.The Yersinia pestis (Y. pestis), strain KIM, Gateway^? clone set consists of 43 plates (plate 2 of this clone set has been discontinued) which contain more than 3600 sequence validated clones from Y. pestis, strain KIM cloned in Escherichia coli (E. coli) DH10B-T1 cells. Each open reading frame was constructed in vector pDONR?221 (Invitrogen?) with an ATG start codon and a TAG stop codon. The sequence was validated by full length sequencing of each clone with greater than 1X coverage and a mutation rate of less than 0.2%. Information related to the use of Gateway^? Clones can be obtained from Invitrogen?. Recombination was facilitated through an attB substrate (attB-PCR product or a linearized attB expression clone) with an attP substrate (pDONR?221) to create an attL-containing entry clone. The entry clone contains recombinational cloning sites, attL1 and attL2 to facilitate gene transfer into a destination vector, M13 forward and reverse priming sites for sequencing and a kanamycin resistance gene for selection. Please refer to the Invitrogen? Gateway^? Technology Manual for additional details.Each inoculated well of the 96-well plate contains approximately 60 ?L of E. coli culture (strain DH10B-T1) in Luria Bertani (LB) Broth containing 50 ?g/mL kanamycin supplemented with 15% glycerol.Note: Production in the 96-well format has increased risk of cross-contamination between adjacent wells. Individual clones should be purified (e.g. single colony isolation and purification using good microbiological practices) and sequence-verified prior to use. BEI Resources cannot confirm or validate any clone not identified on the plate information table found on the Product Information Sheet.

NR-19460?? Francisella tularensis subsp. tularensis, Strain SCHU S4, Gateway? Clone Set, Recombinant in Escherichia coli, Plate 3(Clones)|Francisella tularensis subsp. tularensis|Francisella tularensis subsp. tularensis, Strain SCHU S4, Gateway? Clone Set, Recombinant in Escherichia coli, Plate 3|-80°C or colder|Pathogen Functional Genomics Resource Center at the J. Craig Venter InstituteAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Francisella tularensis subsp. tularensis, Strain SCHU S4, Gateway^? Clone Set, Recombinant in Escherichia coli, Plate 3, NR-19460."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.The Francisella tularensis (F. tularensis) subsp. tularensis, strain SCHU S4, Gateway^? clone set consists of 19 plates which contain 1693 sequence validated clones from F. tularensis subsp. tularensis, strain SCHU S4 cloned in Escherichia coli (E. coli) DH10B-T1 cells. Each open reading frame was constructed in vector pDONR?221 (Invitrogen?) with a native start codon and no stop codon. The sequence was validated by full length sequencing of each clone with greater than 1X coverage and a mutation rate of less than 0.2%.Information related to the use of Gateway^? Clones can be obtained from Invitrogen?. Recombination was facilitated through an attB substrate (attB-PCR product or a linearized attB expression clone) with an attP substrate (pDONR?221) to create an attL-containing entry clone. The entry clone contains recombinational cloning sites, attL1 and attL2 to facilitate gene transfer into a destination vector, M13 forward and reverse priming sites for sequencing and a kanamycin resistance gene for selection. Please refer to the Invitrogen? Gateway^? Technology Manual for additional details.Each inoculated well of the 96-well plate contains approximately 60 ?L of E. coli culture (strain DH10B-T1) in Luria Bertani (LB) Broth containing 50 ?g/mL kanamycin supplemented with 15% glycerol.Note: Production in the 96-well format has increased risk of cross-contamination between adjacent wells. Individual clones should be purified (e.g. single colony isolation and purification using good microbiological practices) and sequence-verified prior to use. BEI Resources cannot confirm or validate any clone not identified on the plate information table found on the Product Sheet.

NR-19278?? Streptococcus pneumoniae, Strain TIGR4, Gateway? Clone Set, Recombinant in Escherichia coli, Plates 1-23(Clones)|Streptococcus pneumoniae|Streptococcus pneumoniae, Strain TIGR4, Gateway? Clone Set, Recombinant in Escherichia coli, Plates 1-23|-80°C or colder|Pathogen Functional Genomics Resource Center at the J. Craig Venter InstituteAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Streptococcus pneumoniae, Strain TIGR4, Gateway^? Clone Set, Recombinant in Escherichia coli, Plates 1-23, NR-19278."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.NR-19278 consists of Plates 1-23 (BEI Resources NR-19568 through NR-19590) of the Streptococcus pneumoniae (S. pneumoniae), strain TIGR4, Gateway^? clone set. Detailed information is available on the Master Clone List.The S. pneumoniae, strain TIGR4, Gateway^? clone set consists of approximately 2029 sequence validated clones from S. pneumoniae, strain TIGR4 cloned in Escherichia coli (E. coli) DH10B-T1 cells. Each open reading frame was constructed in vector pDONR?221 (Invitrogen?) with a native start codon and no stop codon. The sequence was validated by full length sequencing of each clone with greater than 1X coverage and a mutation rate of less than 0.2%.Information related to the use of Gateway^? Clones can be obtained from Invitrogen?. Recombination was facilitated through an attB substrate (attB-PCR product or a linearized attB expression clone) with an attP substrate (pDONR?221) to create an attL-containing entry clone. The entry clone contains recombinational cloning sites, attL1 and attL2 to facilitate gene transfer into a destination vector, M13 forward and reverse priming sites for sequencing and a kanamycin resistance gene for selection. Please refer to the Invitrogen? Gateway^? Technology Manual for additional details.Plate orientation and viability were confirmed for each plate of the set.Every inoculated well of each 96-well plate contains approximately 60 ?L of E. coli culture (strain DH10B-T1) in Luria Bertani (LB) broth containing 50 ?g/mL kanamycin supplemented with 15% glycerol.Clone plates are replicated using a BioMek^? FX robot. Production in the 96-well format has increased risk of cross-contamination between adjacent wells. Individual clones should be purified (e.g. single colony isolation and purification using good microbiological practices) and sequence-verified prior to use. BEI Resources only confirms the clone plate orientation and viability of randomly picked clones. BEI Resources does not confirm or validate individual clone identities provided by the contributor.